Carlton Hofferkamp & Jenks Wealth Management LLC boosted its stake in Merck & Co., Inc. (NYSE:MRK) by 21.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,781 shares of the company’s stock after purchasing an additional 2,273 shares during the quarter. Carlton Hofferkamp & Jenks Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $989,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Financial Avengers Inc. bought a new position in shares of Merck & Co., Inc. in the fourth quarter worth approximately $28,000. Joseph P. Lucia & Associates LLC purchased a new stake in Merck & Co., Inc. during the 4th quarter valued at about $29,000. Flagship Private Wealth LLC purchased a new stake in Merck & Co., Inc. during the 4th quarter valued at about $27,000. Veritas Investment Partners UK Ltd. purchased a new stake in Merck & Co., Inc. during the 4th quarter valued at about $30,000. Finally, Curi Capital purchased a new stake in Merck & Co., Inc. during the 4th quarter valued at about $29,000. 72.86% of the stock is currently owned by institutional investors and hedge funds.

Shares of MRK stock traded up $0.05 on Tuesday, reaching $76.03. The company’s stock had a trading volume of 310,393 shares, compared to its average volume of 11,885,203. The stock’s fifty day simple moving average is $76.83 and its 200-day simple moving average is $78.38. Merck & Co., Inc. has a 1 year low of $71.71 and a 1 year high of $87.80. The company has a current ratio of 1.30, a quick ratio of 1.00 and a debt-to-equity ratio of 0.90. The company has a market capitalization of $192.39 billion, a price-to-earnings ratio of 16.81, a price-to-earnings-growth ratio of 1.89 and a beta of 0.43.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Thursday, April 29th. The company reported $1.40 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.63 by ($0.23). The firm had revenue of $12.08 billion during the quarter, compared to analyst estimates of $12.71 billion. Merck & Co., Inc. had a net margin of 24.33% and a return on equity of 53.83%. Merck & Co., Inc.’s revenue was up .2% on a year-over-year basis. During the same quarter last year, the business earned $1.50 earnings per share. Equities research analysts forecast that Merck & Co., Inc. will post 5.9 earnings per share for the current year.

MRK has been the topic of several research analyst reports. SVB Leerink lowered their target price on shares of Merck & Co., Inc. from $103.00 to $102.00 and set an “outperform” rating on the stock in a research note on Friday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Merck & Co., Inc. in a research note on Friday, February 5th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $97.22.

About Merck & Co., Inc.

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products.

Featured Article: Why do commodities matter?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.